Cargando…

EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma

Detalles Bibliográficos
Autores principales:	Chemlal, Djamila, Varlet, Emmanuel, Machura, Amelie, Ovejero, Sara, Requirand, Guilhem, Robert, Nicolas, Cartron, Guillaume, Alaterre, Elina, Bret, Caroline, Vincent, Laure, Herbaux, Charles, Cavalli, Giacomo, Bruyer, Angélique, De Boussac, Hugues, Moreaux, Jerome
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457196/ https://www.ncbi.nlm.nih.gov/pubmed/37532787 http://dx.doi.org/10.1038/s41375-023-01983-0

Ejemplares similares

RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma
por: Alaterre, Elina, et al.
Publicado: (2021)

P843: METABOLOMIC CHARACTERIZATION OF HUMAN MULTIPLE MYELOMA CELL LINE TO STUDY TUMOR RESISTANCE TO DIFFERENT CLASSES OF THERAPEUTIC AGENTS
por: Steer, A., et al.
Publicado: (2022)

Comprehensive characterization of the epigenetic landscape in Multiple Myeloma
por: Alaterre, Elina, et al.
Publicado: (2022)

P844: CHARACTERIZATION OF MULTIPLE MYELOMA CELL LINES WITH ACQUIRED-RESISTANCE TO PROTEASOME INHIBITORS HIGHLIGHTS A LINK BETWEEN RESISTANCE AND METABOLIC DEREGULATION
por: De Boussac, H., et al.
Publicado: (2022)

CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma
por: Alaterre, Elina, et al.
Publicado: (2017)

The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance
por: Ovejero, Sara, et al.
Publicado: (2022)

Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance
por: Vikova, Veronika, et al.
Publicado: (2019)

EZH2 in normal hematopoiesis and hematological malignancies
por: Herviou, Laurie, et al.
Publicado: (2015)

CD38 in Neurodegeneration and Neuroinflammation
por: Guerreiro, Serge, et al.
Publicado: (2020)

Kinome expression profiling to target new therapeutic avenues in multiple myeloma
por: de Boussac, Hugues, et al.
Publicado: (2020)

CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond
por: Roccatello, Dario, et al.
Publicado: (2020)

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
por: Plesner, Torben, et al.
Publicado: (2020)

Phenotyping and Target Expression Profiling of CD34(+)/CD38(−) and CD34(+)/CD38(+) Stem- and Progenitor cells in Acute Lymphoblastic Leukemia
por: Blatt, Katharina, et al.
Publicado: (2018)

Phenotypic Characterization of Diffuse Large B-Cell Lymphoma Cells and Prognostic Impact
por: Devin, Julie, et al.
Publicado: (2019)

The role of CD38 in HIV infection
por: Lu, Liqi, et al.
Publicado: (2021)

CD38 in Advanced Prostate Cancers
por: Guo, Christina, et al.
Publicado: (2021)

Targeting CD38 for acute leukemia
por: Zhong, Xushu, et al.
Publicado: (2022)

The CD38/NAD/SIRTUIN1/EZH2 Axis Mitigates Cytotoxic CD8 T Cell Function and Identifies Patients with SLE Prone to Infections
por: Katsuyama, Eri, et al.
Publicado: (2020)

Interferon gamma selectively inhibits very primitive CD342+CD38- and not more mature CD34+CD38+ human hematopoietic progenitor cells
Publicado: (1994)

Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model
por: Zannetti, Beatrice Anna, et al.
Publicado: (2020)

CD38: T Cell Immuno-Metabolic Modulator
por: Kar, Anwesha, et al.
Publicado: (2020)

Roles of CD38 in the Immune Response to Infection
por: Glaría, Estibaliz, et al.
Publicado: (2020)

CD38: An Immunomodulatory Molecule in Inflammation and Autoimmunity
por: Piedra-Quintero, Zayda L., et al.
Publicado: (2020)

Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38(+) tumors in mouse models in vivo
por: Fumey, William, et al.
Publicado: (2017)

CD38, CD157, and RAGE as Molecular Determinants for Social Behavior
por: Higashida, Haruhiro, et al.
Publicado: (2019)

Role of Polycomb Complexes in Normal and Malignant Plasma Cells
por: Varlet, Emmanuel, et al.
Publicado: (2020)

Decreased levels of T follicular helper (CD4+CXCR5+) cells and CD27+CD38+ and CD27+CD38− B cells in ankylosing spondylitis patients correlate with markers of inflammation
por: Lejon, Kristina, et al.
Publicado: (2022)

Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation
por: Costa, Federica, et al.
Publicado: (2017)

Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma
por: Fayon, Maxime, et al.
Publicado: (2021)

CD38‐Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells
por: Liao, Chan, et al.
Publicado: (2023)

Tetraspanin Family Member, CD82, Regulates Expression of EZH2 via Inactivation of p38 MAPK Signaling in Leukemia Cells
por: Nishioka, Chie, et al.
Publicado: (2015)

Responses of CD27(+)CD38(+) plasmablasts, and CD24(hi)CD27(hi) and CD24(hi)CD38(hi) regulatory B cells during primary dengue virus 2 infection
por: Lei, Chenshuang, et al.
Publicado: (2021)

CD34 and CD38 are prognostic biomarkers for acute B lymphoblastic leukemia
por: Jiang, Zhiwu, et al.
Publicado: (2016)

The Roles of CD38 and CD157 in the Solid Tumor Microenvironment and Cancer Immunotherapy
por: Wo, Yu Jun, et al.
Publicado: (2019)

Ligation of CD38 suppresses human B lymphopoiesis
Publicado: (1995)

The Roles of Oxytocin and CD38 in Social or Parental Behaviors
por: Lopatina, Olga, et al.
Publicado: (2013)

Targeting CD38 alleviates tumor-induced immunosuppression
por: Tai, Yu-Tzu, et al.
Publicado: (2017)

Immuno-targeting the multifunctional CD38 using nanobody
por: Li, Ting, et al.
Publicado: (2016)

Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
por: Martin, Thomas G., et al.
Publicado: (2019)

The Anti-CD38 Antibody Therapy in Multiple Myeloma
por: Petrucci, Maria Teresa, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ofbvf0bqlfk6l3lispau6ir904